Ryuvidine
Ryuvidine is a potent inhibitor of SET domain-containing protein 8 (SETD8) with an IC50 of 0.5 µM and suppresses monomethylation of H4K20. Ryuvidine also inhibits CDK4 with an IC50 of 6.0 μM. Ryuvidine also inhibits KDM5A and blocks DNA synthesis. Ryuvidine has anticancer activity against tumors such as breast cancer. Ryuvidine improves arthritis[1][2][3][4][5].
Product Specifications
CAS Number
265312-55-8
UNSPSC
12352005
Target
CDK; DNA/RNA Synthesis; Histone Demethylase; Histone Methyltransferase
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/ryuvidine.html
Purity
99.40
Solubility
DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C1C=C(C(C2=C1SC(C)=N2)=O)NC3=CC=C(C)C=C3
Molecular Formula
C15H12N2O2S
Molecular Weight
284.33
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK4
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
HCG-beta (Pregnancy & Choriocarcinoma Marker) (HCGb/1985R), Biotin conjugate, 0.1mg/mL
Spastin (Sp 6C6), CF405S conjugate, 0.1mg/mL
Thyroglobulin (2H11), CF594 conjugate, 0.1mg/mL
Angiotensin I Converting Enzyme (ACE) / CD143 (9B9), CF488A conjugate, 0.1mg/mL
